NEW YORK (GenomeWeb News) – Bio-Rad Laboratories reported after the close of the market on Tuesday that its first-quarter revenues ramped up 3 percent year over year, as the company fell short of consensus analyst estimates on the top and bottom lines.

The Hercules, Calif.-based firm said that revenues for the three months ended March 31 totaled $499.7 million, up from $486.3 million a year ago, but below the average Wall Street estimate of $506.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.